APRI (Aprinoia Therapeutics) Beginning Cash Position: $7.73 Mil (As of Dec. 2023)


What is Aprinoia Therapeutics Beginning Cash Position?

Aprinoia Therapeutics APRI Beginning Cash Position is $7.73 Mil as of Dec. 2023.

Aprinoia Therapeutics's Beginning Cash Position for the quarter that ended in Dec. 2023 was $7.73 Mil.

Aprinoia Therapeutics's quarterly Beginning Cash Position declined from Dec. 2022 ($7.69 Mil) to Jun. 2023 ($1.22 Mil) but then increased from Jun. 2023 ($1.22 Mil) to Dec. 2023 ($7.73 Mil).

Aprinoia Therapeutics's annual Beginning Cash Position increased from Dec. 2021 ($2.86 Mil) to Dec. 2022 ($9.67 Mil) but then declined from Dec. 2022 ($9.67 Mil) to Dec. 2023 ($1.22 Mil).

Aprinoia Therapeutics Beginning Cash Position Related Terms

Aprinoia Therapeutics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Aprinoia Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprinoia Therapeutics Beginning Cash Position Chart

Aprinoia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Beginning Cash Position
2.86 9.67 1.22

Aprinoia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Beginning Cash Position 0.00 9.67 7.69 1.22 7.73

Aprinoia Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $7.73 Mil mean?
Aprinoia Therapeutics (APRI) has a Beginning Cash Position of $7.73 Mil as of Dec. 2023. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Aprinoia Therapeutics and its competitors.
Is Aprinoia Therapeutics' Beginning Cash Position too high?
Aprinoia Therapeutics' current Beginning Cash Position is $7.73 Mil.
How does Aprinoia Therapeutics' Beginning Cash Position compare to ?
Aprinoia Therapeutics' Beginning Cash Position of $7.73 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Aprinoia Therapeutics and its competitors. Aprinoia Therapeutics's current Beginning Cash Position is $7.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprinoia Therapeutics stock overvalued right now?
Aprinoia Therapeutics (APRI) has a current Beginning Cash Position of $7.73 Mil. The current Beginning Cash Position is $7.73 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Aprinoia Therapeutics (APRI), the current Beginning Cash Position is $7.73 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aprinoia Therapeutics Business Description

Comparable Companies
Address 245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.